Other · developed by Bambusa Therapeutics
BBT001 is an investigational agent studied in chronic spontaneous urticaria.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07717905 | Phase 1/2 | Chronic Spontaneous Urticaria | Recruiting | BBTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Spontaneous Urticaria
Updated Nov 8, 2026. Something wrong or missing? Report it on the BBTX page.
See BBTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BBTX catalysts and pipeline →